Asceneuron SA’s Post

View organization page for Asceneuron SA, graphic

2,865 followers

#Asceneuron_sa announces $100 million oversubscribed Series C financing!   Today we announce that we have successfully secured a Series C financing, led by Novo Holdings with new investment from EQT Life Sciences, OrbiMed and SR One Capital Management, alongside participation from existing investors M Ventures , Sofinnova Partners, @GSK Equities Investment Limited and Johnson & Johnson Innovation JJDC Inc.   The funds will be used to advance our lead asset #ASN51, an oral small molecule drug designed to inhibit OGA into Phase 2 clinical development for the treatment of Alzheimer’s disease.   Click the link in the comments below to read the press release and discover more about Asceneuron’s groundbreaking clinical pipeline of O-GlcNAcase (#OGA) inhibitors for the treatment of #neurodegenerative diseases.   #neurodegeneration #ALS #alzheimers #parkinson #dementia #financing 

  • No alternative text description for this image
Bruno Permanne

Senior Director, Head of Preclinical Development at Asceneuron S.A., Lausanne, Switzerland

3mo

I’m so proud to be part of such a great team and so thrilled to advance our molecules to tackle new challenges and reach Alzheimer’s patients.

Manfred Schneider PhD, DABT

Director and Founder "AUC Consulting" - Piraeus, Athens, Greece

3mo

I am so proud to be part of this Amazing Team! What an achievement. We are getting closer and closer to helping Alzheimer's patients and their families.

Sandra MILLET

Change Management / Communication

3mo

This investment marks a significant milestone in our journey to bring groundbreaking treatments to patients suffering from neurodegenerative diseases. It’s a testament to the hard work, dedication, and expertise of our incredible #Asceneuron Team 💙 Grateful to our investors for their trust in our vision and looking forward to bring #OGA inhibitor ASN51 to patients. #Financing #Teamwork #alzheimer

Fantastic achievement in a rapidly evolving field! Congratulations team Asceneuron SA!

Jeanne Bolger

Life Sciences Consultant and Board member

3mo

Absolutely thrilled to hear the news of this $100M Series C financing to advance Asceneuron SA ‘s lead OGA inhibitor through clinical development. Having been at the table at the founding of this company with JJDC, it’s hugely rewarding to see my investor colleagues at Novo Holdings , EQT Life Sciences and OrbiMed seeing the potential of this program to address huge unmet needs in this devastating disease. Congratulations to Barbara A. And the entire Asceneuron SA team, to Hakan Goker , Henrijette Richter , Amit Shah , Deborah Harland , Catherine Moukheibir and Lior Teitelbaum for your patient commitment to this company. It takes a village! To Naveed Siddiqi , Philip Scheltens and Dina Chaya , welcome to this highly performant Board. Wishing you all every success in this next phase of Asceneuron SA ‘s important journey! The patients are waiting! #alzheimer’s disease #neurodegeneration #ogainhibitors

Vanessa Teachout

Head, Clinical Operations at Asceneuron SA

3mo

With full speed ahead to Phase 2, I am thankful to be on an amazing #Asceneuron Team, supported by experienced executive leadership and a dedicated board of directors. Grateful for our investors' trust and excited to bring #ASN's #OGA inhibitor, ASN51, to patients. #Alzheimers #Asceneuron #Asceneuron_SA

Naveed Siddiqi

Senior Partner, Novo Holdings

3mo

Congratulations! Thrilled to be joining you on the Board and as an investor on this important mission!

Jean-Francois Stallaert

Clinical Portfolio Execution | Delivery Excellence | Team-Oriented | Bilingual (French/English)

3mo

Great news! Well done 👍🏻

Congratulations to Asceneuron SA on securing this impressive Series C financing! 🚀 We are proud to have such an innovative company within our EPFL Innovation Park community.

See more comments

To view or add a comment, sign in

Explore topics